Coagulation abnormalities in dogs with neoplastic disease.

Area of Science:

• Veterinary Medicine
• Hematology
• Oncology

Background:

• Hemostatic abnormalities are common in cancer patients.
• Previous studies have indicated potential links between neoplasia and coagulation disorders in dogs.

Purpose of the Study:

• To screen untreated tumor-bearing dogs for hemostatic abnormalities.
• To determine the prevalence of various coagulation test results in dogs with different types of cancer.

Main Methods:

• Conventional laboratory methods were employed to assess coagulation parameters.
• One hundred dogs with untreated neoplasms were studied, excluding those with clinical bleeding.
• Coagulation tests included platelet counts, fibrinogen levels, activated partial thromboplastin time, prothrombin time, thrombin time, protamine sulfate reaction, fibrin degradation products, euglobulin lysis time, and schistocyte evaluation.

Main Results:

• Eighty-three percent of the dogs exhibited one or more abnormal coagulation tests.
• Common findings included thrombocytopenia (36 dogs), hypofibrinogenemia (25 dogs), hyperfibrinogenemia (25 dogs), and prolonged activated partial thromboplastin time (32 dogs).
• Other observed abnormalities included shortened prothrombin time, prolonged thrombin time, positive protamine sulfate reaction, increased fibrin degradation products, accelerated euglobulin lysis time, and schistocytes.

Conclusions:

• The majority of dogs with advanced neoplasms are likely to have abnormal coagulation tests.
• These findings suggest a significant association between neoplastic disease and hemostatic system dysregulation in dogs.
• Further investigation into the clinical implications of these coagulation abnormalities in tumor-bearing dogs is warranted.